Elaaj Bio advances gene therapy for CDKL5 deﬁciency disorder

May 6, 2026

Elaaj Bio, a wholly owned subsidiary of the nonproﬁt Loulou Foundation, has entered into a partnership with Viralgen Vector Core SL to advance a gene therapy program for CDKL5 deﬁciency disorder.

BioWorld Science Collaboration Genetic/congenital Neurology/psychiatric Gene therapy

Today's news in brief

BioWorld

BioWorld briefs for May 19, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Authorities work to quickly sequence Ebola species in latest outbreak

BioWorld

If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...